Q1 2025 Financial Results Presentation May 6, 2025 1 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955 ("PSLRA") relating to, among other things, continued development and expansion of our business, projected financial performance including sales and revenue growth, potential results of our Phase 1b study of R289 in R/R lower-risk MDS, future Phase 2 studies of olutasidenib in recurrent glioma, potentia ...